Capricor Therapeutics (CAPR) Change in Accured Expenses (2010 - 2026)

Capricor Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 334.27% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $1.6 million (down 51.28% YoY), while the FY2025 annual figure was $6.0 million, up 208.27% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.1 million, down from $2.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.2 million in Q4 2025, with the low at -$3.1 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $501815.0 (2023), against an average of $464028.2.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 83134.6% in 2025, then slumped 334.27% in 2026.
• Capricor Therapeutics' Change in Accured Expenses stood at $982327.0 in 2022, then plunged by 155.15% to -$541709.0 in 2023, then surged by 406.44% to $1.7 million in 2024, then surged by 30.61% to $2.2 million in 2025, then sank by 242.11% to -$3.1 million in 2026.
• Business Quant data shows CAPR's Change in Accured Expenses at -$3.1 million in Q1 2026, $2.2 million in Q4 2025, and $971647.0 in Q3 2025.